Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Investing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Investing cash flow grows 28.6% year over year

Q4 FY2025 investing cash flow of CN¥302.52M (cash outflow) rose 28.6% year over year. Over 3 fiscal years it compounded at +37.5% a year.

Context

  • Investing cash flow amounted to 179.1% of revenue in FY2025, up 142.1 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥302.52M— QoQ
Last fiscal yearDec 2025
-CN¥1B+176.2% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.6%——
1 year+176.2%——
3-year CAGR+37.5%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

CNY · from the cash flow

Latest · FY2025
(1B) CNY
Year-over-year change
-176.2%

Investing Cash Flow vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +176.2% is the 2nd highest of 10, against a peer median of -124.8%.
  • Investing cash flow amounts to 179.1% of revenue for AAPG, versus a peer median of 48.4%.
AAPG Competitors
Investing Cash Flow for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥1B CNY+176.2%+37.5%179.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026$796.04M USD-641.8%——
IMRXImmuneering CorporationLTM Mar 2026$151.8M USD-3115.8%——
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$109.11M USD+258.7%—48.4%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$104.47M USD-32.9%——
NUVBNuvation Bio Inc.LTM Jun 2026$47.18M USD-124.8%+16.2%27.8%
ZLABZai Lab LimitedLTM Jun 2026$39.05M USD-28.3%-9.8%8.7%
VSTMVerastem, Inc.LTM Mar 2026$25.64M USD-188.4%—51.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$21.57M USD-169.0%—61.9%
ANLAdlai Nortye Ltd.LTM Jun 2024$4.81M USD——74.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$1.1M USD-83.6%+75.8%0.2%
Peer median (excluding AAPG) —-124.8%+16.2%48.4%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(832.25M)(887.17M)(932.86M)(395.26M)(1.24B)
Depreciation & Amortization28.33M62.92M93.2M93.17M86.48M
Deferred Income Tax00000
Stock-Based Compensation46.97M22.11M31.5M20.92M20.87M
Change in Working Capital(74.91M)104.41M(9.15M)110.97M(143.5M)
Accounts Receivables(53.97M)(388K)(91.54M)62.75M(169.8M)
Inventory(3.93M)(5.52M)(6.72M)9.57M(26.2M)
Accounts Payables024.7M(23.11M)19.52M14.77M
Other Working Capital(17.01M)85.62M112.22M19.13M37.72M
Other Non-Cash Items227.18M43.82M91.23M58.84M98.07M
Operating Cash Flow(604.68M)(653.92M)(726.08M)(111.36M)(1.17B)
Capital Expenditures(436.63M)(236.96M)(56.84M)(24.29M)(27.57M)
Acquisitions (Net)(36.2M)(20M)(20M)(25.52M)(43.34M)
Purchases of Investments(1.78B)(130M)0(312.23M)(929.14M)
Sales of Investments1.79B0000
Other Investing Activities(879K)(31.32M)88.03M(312.23M)0
Investing Cash Flow(466.52M)(384.61M)21.92M(362.04M)(1B)
Debt Repayment548.59M695.87M(13.36M)(145.34M)307.26M
Common Stock Issued1.3B0470.08M533.94M2.3B
Common Stock Repurchased(25.87M)(26.78M)(5.92M)0(9.04M)
Dividends Paid00000
Other Financing Activities(41.97M)(49.83M)(82.05M)(73.83M)(63.04M)
Financing Cash Flow1.78B619.27M368.75M314.77M2.54B
Effect of Forex Changes(23.28M)58.01M27.81M13.68M(63.24M)
Net Change in Cash686.91M(361.25M)(307.59M)(144.95M)302.68M
Free Cash Flow(1.04B)(890.88M)(782.92M)(135.65M)(1.2B)

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.